{
    "type": "ETP",
    "ucits": false,
    "replication_method": "physical",
    "leverage": true,
    "derivatives": false,
    "swaps": false,
    "inverse": true,
    "complex_factors": [
        "Leverage",
        "Inverse Exposure",
        "Daily Compounding",
        "High Risk Rating (7/7)",
        "Physical Short Positions",
        "Compounding Effect"
    ],
    "classification": "complex",
    "supporting_data": "The product is a Collateralised Exchange Traded Security (ETP) designed to provide -3x the daily return of the iShares Silver Trust, achieved through physical short positions in the underlying iShares Silver Trust stock and cash balances, with no use of derivatives or swaps. The replication method is physical, not synthetic. However, the product employs significant leverage (-3x) and inverse exposure, with daily rebalancing and compounding effects that can cause returns over periods longer than one day to deviate significantly from the expected multiple of the underlying asset's return. The risk indicator is at the highest level (7/7), indicating very high risk. The product is not UCITS compliant. The KIID and PRIIPs documents emphasize the complexity of the leverage and inverse strategy, the compounding effect, and the need for sophisticated investors who can monitor positions daily. There is no capital protection, and investors can lose their entire investment. No swaps or derivative instruments are used inherently in the strategy, but the leverage and inverse exposure alone classify the product as complex under MiFID II. The product's complexity arises primarily from the leverage, inverse exposure, and the compounding effect rather than derivative or swap usage. The product is structured as an ETP (debt security) with physical short positions, not an ETF. The PRIIPs KID includes a comprehension warning and highlights the product's complexity and risk. Therefore, despite physical replication and no derivative usage, the leverage and inverse nature, combined with the high risk and compounding effects, make this product complex under MiFID II."
}